BridgeBio Oncology Therapeutics, Inc. (BBOT) said the U.S. Food and Drug Administration has granted Fast Track designation to BBO-11818 for the treatment of adults with advanced KRAS-mutant pancreatic ductal adenocarcinoma.
The designation follows preliminary data released in January 2026, in which BBO-11818 monotherapy showed a confirmed partial response in pancreatic cancer patients.
The company said anti-tumor activity was observed across dose levels and tumor types, with tumor reductions at higher doses and a generally favorable and differentiated safety profile during dose escalation.
BBO-11818 is currently being evaluated in the Phase I KONQUER-101 trial in patients with locally advanced unresectable or metastatic KRAS-mutant solid tumors, with updated data expected in the second half of 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.